baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

AnaptysBio/ US0327241065 /

6/3/2024 5:38:30 PM	Chg. +0.34	Volume	Bid-	Ask-	High	Low
24.26USD	+1.42%	5,181 Turnover: 128,015.23	-Bid Size: -	-Ask Size: -	25.00	24.05

GlobeNewswire 5/9 Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/9 Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...

GlobeNewswire 5/9 Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...

GlobeNewswire 3/26 Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...

GlobeNewswire 3/11 Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 2/29 Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

GlobeNewswire 1/31 Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

GlobeNewswire 11/27/2023 Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Po...

GlobeNewswire 11/11/2023 SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AnaptysBio, Inc. (NASDAQ: ANAB) and En...

GlobeNewswire 11/7/2023 Anaptys Named a BioSpace 2024 Best Places to Work Winner

GlobeNewswire 11/7/2023 INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into AnaptysBio, Inc.; Urges AnaptysBio’s...

GlobeNewswire 11/2/2023 Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 11/1/2023 Anaptys Announces Participation in November Investor Conferences

GlobeNewswire 10/11/2023 Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

GlobeNewswire 10/9/2023 Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 2...

GlobeNewswire 10/9/2023 Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Genera...

GlobeNewswire 9/18/2023 AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

GlobeNewswire 9/12/2023 AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

GlobeNewswire 3/21/2022 AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

GlobeNewswire 3/14/2022 AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

GlobeNewswire 3/7/2022 AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Updat...

GlobeNewswire 1/6/2022 Recludix Pharma Announces Scientific Advisory Board

GlobeNewswire 1/5/2022 AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 11/29/2021 AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

GlobeNewswire 11/16/2021 AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

AnaptysBio/ US0327241065 /

If you wish to receive reply to your feedback, please provide your email address.